文章摘要

脑循环系统治疗仪联合阿立哌唑对女性精神分裂症患者认知和社会功能的影响

作者: 1郑昌胜, 1童庆好, 1王安江, 2赵娟娟
1 皖西卫生职业学院附属医院精神科,安徽 六安 237000
2 皖西卫生职业学院附属医院康复治疗室,安徽 六安 237000
通讯: 郑昌胜 Email: 331639814@qq.com
DOI: 10.3978/j.issn.2095-6959.2022.04.014

摘要

目的:探讨脑循环系统治疗仪联合阿立哌唑对女性精神分裂症(schizophrenia,SCH)患者认知和社会功能的影响。方法:选取2019年6月至2021年5月皖西卫生职业学院附属医院精神疾病科女病区收治的140例女性SCH住院患者,随机数表法分成药物组与联合组,每组70例。药物组给予阿立哌唑单药治疗,联合组给予脑循环系统治疗仪联合阿立哌唑治疗,持续6周。比较两组阳性与阴性症状量表(Positive and Negative Symptom Scale,PANSS)评分、临床疗效、认知功能成套测试(MATRICS Consensus Cognitive Battery,MCCB)和个人与社会功能量表(Personal and Social Function Scale,PSP)评分。结果:治疗6周后,两组PANSS总分和3个分量表均较治疗前下降(P<0.05),且联合组阳性症状、一般精神病性症状和PANSS总分低于药物组,总有效率高于药物组(均P<0.05)。治疗6周后,两组MCCB各认知域评分均较治疗前升高(P<0.05),联合组工作记忆、言语学习和记忆、推理和问题解决能力、社会认知4个认知域评分高于药物组(P<0.05)。联合组治疗6周后PSP评分高于治疗前(P<0.05),也明显高于药物组(P<0.05)。结论:脑循环系统治疗仪联合阿立哌唑不仅能明显减轻SCH患者PANSS评分,而且有助于改善认知功能和社会功能。
关键词: 精神分裂症;女性;脑循环系统治疗仪;阿立哌唑;认知功能;社会功能

Effects of cerebral circulation function therapy device combined with aripiprazole on cognitive and social function in female patients with schizophrenia

Authors: 1ZHENG Changsheng, 1TONG Qinghao, 1WANG Anjiang, 2ZHAO Juanjuan
1 Department of Psychiatric, Affiliated Hospital of West Anhui Health Vocational College, Lu’an Anhui 237000, China
2 Rehabilitation Treatment Room, Affiliated Hospital of West Anhui Health Vocational College, Lu’an Anhui 237000, China

CorrespondingAuthor: ZHENG Changsheng Email: 331639814@qq.com

DOI: 10.3978/j.issn.2095-6959.2022.04.014

Abstract

Objective: To investigate the effect of cerebral circulation function therapy device combined with aripiprazole on cognitive and social function in female patients with schizophrenia (SCH). Methods: A total of 140 female patients with SCH admitted to the Department of Mental Diseases of the Affiliated Hospital of Wanxi Health Vocational College from June 2019 to May 2021 were selected and randomly divided into a drug group and a combined group by random number table method, with 70 cases in each group. The drug group was given aripiprazole monotherapy, and the combined group was treated with cerebral circulation function therapy device combined with aripiprazole for 6 weeks. The scores of Positive and Negative Symptom Scale (PANSS), clinical efficacy, MATRICS Consensus Cognitive Battery (MCCB), and Personal and Social Function Scale (PSP) were compared between the two groups. Results: After 6 weeks of treatment, the total scores of PANSS and three subscales in the two groups decreased compared with those before treatment (P<0.05). The positive symptoms, general psychopathological symptoms and total scores of PANSS in the combined group were lower than those in the drug group, and the total effective rate was higher than that in the drug group (all P<0.05). After 6 weeks of treatment, the scores of each cognitive domain of MCCB in the two groups were higher than those before treatment (P<0.05). The scores of working memory, speech learning and memory, reasoning and problem-solving ability, and social cognition in the combined group were higher than those in the drug group (P<0.05). After 6 weeks of treatment, the PSP score in the combined group was higher than that before treatment (P<0.05), and it was also significantly higher than that in the drug group (P<0.05). Conclusion: Cerebral circulatory system therapeutic instrument combined with aripiprazole can not only significantly reduce PANSS score in patients with Sch, but also help to improve cognitive and social function.
Keywords: schizophrenia; female; cerebral circulation function therapy device; aripiprazole; cognitive function; social function